STENTiT, Vivolta and Corbion announced their first collaboration to develop a regenerative stent for clinical use, with an initial focus on the treatment of patients suffering from critical limb ischemia. The announcement by members of SBMC was made at the RegMed XB Pilot Factory Meeting held at the Philips Stadium in Eindhoven, Netherlands.
The project proposal will enable translational steps needed to move the regenerative stent another step closer towards clinical application. STENTiT, Vivolta and Corbion are collaborating for the ultimate purpose of manufacturing batches of clinical-grade stents together.
The first indication targeted for application of the regenerative stent is the treatment of patients suffering from critical limb ischemia, a progressive form of peripheral artery disease in which blood flow to the foot is severely compromised. With the regenerative stent, the consortium partners aim to provide a solution that instantly restores blood flow to the foot using an endovascular support device composed of bioresorbable nanofibers capable of regenerating the artery from within.
Since the device is composed solely of bioresorbable nanofibers, its porous structure will allow the influx of circulating blood cells, triggering a natural healing response by which new vascular tissue is rebuilt. In this way, the implant facilitates vascular regeneration to restore the affected artery from the inside out, then subsequently resorbs safely over time.
The initiative aims to provide superior long-term clinical outcomes and to prevent hundreds of thousands of amputations worldwide each year. This project fits into the scope of RegMedXB and SBMC by using smart biomaterials to create endovascular band-aids that can persuade the body to regenerate affected blood vessels.
Attachment
